Innate immune function during antineoplastic treatment is associated with 12-months survival in non-small cell lung cancer.

ABSTRACT:

Introduction

The immune system has proven to be a key player in the progression as well as containment of cancer with new treatment strategies based on immunotherapy targeting this interaction. Assessing immune function could reveal critical information about the immune response to therapeutic interventions, revealing predictive biomarkers for tailored care and precision medicine.

Methods

We investigated immune function in 37 patients with inoperable non-small cell lung cancer (NSCLC) undergoing treatment with PD-L1 immune checkpoint inhibitor (ICI), chemotherapy (CT) or chemo-radiotherapy (CT/RT). Blood samples before (day 0) and during therapy (day 7, 21 and 80) were investigated by a standardized immunoassay, TruCulture®.

Results

Outcomes revealed a developing inna

SUBMITTER: Ryssel H 

PROVIDER: S-EPMC9791214 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature